How have AKBA and GALT total returns compared?

Over the past 10 years, AKBA delivered -20.53% and GALT delivered 13.41% annualized total return. Past performance doesn't predict future results.

Akebia Therapeutics, Inc. (AKBA) vs Galectin Therapeutics Inc. (GALT)

A side-by-side comparison of Akebia Therapeutics, Inc. and Galectin Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AKBA

Akebia Therapeutics, Inc.

$238M

$0.89HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT

GALT

Galectin Therapeutics Inc.

$242M

$3.67HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT

Total return — AKBA vs GALT

growth of $100 · dividends reinvested · last 10y

AKBA -89.7% (-20.4%/yr)GALT +293.3% (+14.7%/yr)GALT compounded faster over this window

Log scale — wide-divergence pair

AKBA GALT

AKBA vs GALT: by the numbers

•GALT is the larger company ($242M vs $238M market cap).
•Both run net losses; GALT's is the smaller (0.00% vs -13.54% net margin).

Metrics side by side

Valuation

Metric	AKBA	GALT
P/S ratio	1.09	N/A
P/B ratio	9.51	N/A
FCF yield	16.89%	N/A

Profitability

Metric	AKBA	GALT
Gross margin	79.48%	0.00%
Operating margin	9.95%	0.00%
Net margin	-13.54%	0.00%
ROE	-118.58%	N/A
ROIC	-7.08%	-1718.59%

Growth (annualized)

Metric	AKBA	GALT
Revenue CAGR (5Y)	-0.26%	N/A
Total return CAGR (5Y)	-20.07%	0.60%

Frequently asked

How have AKBA and GALT total returns compared?: Over the past 10 years, AKBA delivered -20.53% and GALT delivered 13.41% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AKBA analysis Full GALT analysis Interactive comparison tool

Dig into the metrics

Akebia Therapeutics ROE Galectin Therapeutics ROE Akebia Therapeutics operating margin Galectin Therapeutics operating margin Akebia Therapeutics revenue growth Galectin Therapeutics revenue growth Akebia Therapeutics free cash flow Galectin Therapeutics free cash flow

Akebia Therapeutics & Galectin Therapeutics appear in these rankings

Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.